patients who are neutropenic after receiving conventional dosages of chemotherapy without BMT 7 have shifted from gram-negative to gram-positive bacteria, which currently Antimicrobial prophylaxis against gram-positive bacteremia (GPB) following BMT may prevent infections but account for approximately 60% of all bacteremias in BMT recipients. 1 The systematic use of central venous catheters promote antimicrobial resistance. In a sequential cohort study involving 289 consecutive BMT recipients we has increased the incidence of infections due to coagulasenegative staphylococci, which in many centers have compared three protocols for prevention of GPB (vancomycin prophylaxis, penicillin/cefazolin prophybecome the most common organisms isolated from blood cultures.
laxis, and no specific GPB prophylaxis) with respect to incidence of GPB, mortality, and vancomycin use. GPB In addition, beginning in the early 1980s viridans-group streptococcal bacteremia, sometimes complicated by septic was associated with increased mortality (27% vs 15%; P = 0.02), but contributed to only five of 52 deaths in shock, emerged as a significant problem among neutropenic patients, including BMT recipients. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In the early 1980s, the study population, and only one of 15 subjects with viridans streptococcal bacteremia developed fatal septic viridans streptococcal bacteremia occurred in 123 (15%) of 832 consecutive BMT recipients at the University of Minshock. Vancomycin prophylaxis reduced the incidence of GPB (11%) compared to penicillin/cefazolin (27%) nesota Hospital and Clinic (UMHC). 5 Ten (8%) of these patients with viridans streptococcal bacteremia developed or no prophylaxis (40%) (all P Ͻ 0.03), but did not significantly reduce mortality. The incidence of fungemia, septic shock, and six died as a consequence of their shock or from subsequent complications. 9 In an effort to decrease gram-negative bacteremia, and infection-associated mortality was unaffected by GPB prophylaxis. Vancoviridans streptococcal and other gram-positive infections, prophylactic vancomycin (vanco) for all patients undermycin use was substantially greater in the vancomycin prophylaxis group. We conclude that in comparison going BMT at UMHC was instituted empirically in 1983. 10 Other investigators subsequently presented evidence that with vancomycin prophylaxis, BMT support regimens that do not include vancomycin prophylaxis allow prophylaxis with vancomycin 6 or penicillin 11 is effective in preventing gram-positive infections in BMT recipients. reduced overall vancomycin use without an apparent increase in early post-BMT mortality, despite the Since 1990, vancomycin-resistant enterococci have emerged as a challenging new pathogen in many hospitals greater associated frequency of GPB. Keywords: gram-positive bacterial infections; bactereincluding UMHC. 24, 25 These organisms, which can infect BMT recipients as well as other patients, 26 present physmia; streptococcal infections; drug resistance, microbial; vancomycin; staphylococcal infections icians with the frightening prospect of infections for which no effective antimicrobial therapy may be available. In February 1994, restrictions on the use of vancomycin were established at UMHC as part of a multipronged effort to In patients undergoing BMT, early treatment-associated control an outbreak of vancomycin-resistant enteromortality ranges from 5 to 20%, with infectious complicocci. 25 ,27 From 14 February 1994 to June 1994, neither cations responsible for the majority of deaths. 1 The use of vancomycin nor any other agent was used specifically for prophylactic antibiotics directed against gram-negative, prophylaxis against gram-positive bacteremia (GPB) in viral, and fungal pathogens has decreased the incidence of BMT recipients at UMHC (BMT recipients did continue to these infections. [1] [2] [3] [4] In recent years, the most frequent agents receive prophylaxis with trimethoprim-sulfamethoxazole, of bacterial infection among BMT recipients 5, 6 and in which is active against many gram-positive organisms). In June 1994, a fatal case of viridans streptococcal bacteremia with septic shock in a BMT recipient prompted reinstitution GPB prophylaxis in BMT recipients, 6, 10, 11, 15 this sequential day +30 following BMT (single positive blood cultures among UMHC BMT recipients are commonly associated use of three alternative GPB prophylaxis protocols provided a unique opportunity to evaluate these three with fever plus other clinical manifestations of systemic infection, and often involve organisms that are unlikely to approaches ('vanco', 'none' and 'pen/cef') in a prospective, sequential cohort study to determine their impact on GPB, be contaminants (unpublished data, DW), hence are regarded clinically as indicative of true bacteremia). Organmortality and vancomycin use. We also sought to identify predictors of GPB and to determine the impact of GPB on isms were identified to the level of genus (eg Corynebacterium sp.), sub-genus (eg coagulase-negative mortality in the context of BMT. staphylococcus), or species (eg Streptococcus mitis), according to the clinical microbiology laboratory's standard protocols. The same organism (by identification and Patients and methods antibiogram), if isolated within a 14 day-period after the first positive blood culture, was considered to be part of Subjects the same bacteremia episode, but if more than 14 days had All pediatric and adult BMT recipients at the UMHC during elapsed since the first positive culture the new isolate was the 17-month study period August 1993 to December 1994 considered to represent a separate event. Different bacterial were included as subjects, with the exception of seven species isolated on different days were considered to reppatients who received BMT during the 2 week transition resent different events, regardless of the time interval. period from 'vanco' prophylaxis to 'none', when prophylaxis regimens used on the BMT service were not uniform.
Prophylaxis regimens and cohorts There were no significant changes in the conditioning regiProtocol GPB prophylaxis was initiated at day Ϫ1 and conmens used during the study period.
tinued until engraftment, defined as an absolute neutrophil count of Ͼ500 × 10 9 /l for 3 consecutive days. Vancomycin
Data collection
prophylaxis was given intravenously as 1 g every 12 h (adults; 15 mg/kg for children Ͻ40 kg). Pen/cef prophyThe University of Minnesota BMT Database systematically laxis was given as penicillin VK 250 mg every 6 h orally and prospectively collects data on consecutive BMT recipi-(125 mg per dose if Ͻ27 kg), penicillin G 50 000 U/kg (up ents at UMHC. BMT Database records were searched to to 2 million U/dose) every 6 h intravenously, or cefazolin identify patients who had GPB documented during the 25 mg/kg (up to 1 g/dose) every 8 h intravenously. study period. Clinical data (gender, age, transplant type, In addition to protocol GPB prophylaxis, all subjects underlying disease, time to engraftment and clinical (including those in the 'none' cohort) received prophylactic course), microbiological data from blood cultures trimethoprim/sulfamethoxazole as 160 mg/800 mg twice (microorganisms isolated, time of isolation), and (where daily by mouth, which was changed to four doses per week applicable) cause of death determinations were extracted (twice daily on Mondays and Tuesdays) when intravenous from the Database for all BMT recipients during this peranti-gram-negative therapy was instituted. Antifungal iod. Hospital medical records of subjects who had viridans prophylaxis with fluconazole was administered according streptococcal bacteremia within the study period and who to the guidelines of ongoing trials (for example see Ref. 4) . died by day 100 post-BMT were reviewed by one of the investigators to provide an independent assessment of whether death was related to the bacteremia. Hospital pharEmpirical therapy for fever macy records of 50 patients in the 'vanco' group and of all According to BMT service protocols, subjects who subjects in the 'none' and 'pen/cef' groups were reviewed developed a first febrile episode were given an intravenous to document the actual antimicrobial therapy administered.
antibacterial regimen with gram-negative activity (usually ceftazidime alone, or tobramycin plus piperacillin). In the Blood cultures 'vanco' group, vancomycin was continued (as above) until engraftment, regardless of the etiology of the fever (ie conTwo sets of blood cultures, each set including one aerobic tinued as prophylaxis if no vancomycin-requiring organism and one anaerobic bottle, were collected for initial febrile was isolated). In the 'none' and 'pen/cef' groups, intraepisodes while patients were neutropenic. Additional paired venous vancomycin was started empirically (dosed as for sets of cultures were collected for subsequent fever epivancomycin prophylaxis) along with the gram-negative sodes, with a maximum of three sets per 24 h period. Blood regimen, replacing pen/cef in the 'pen/cef' group. If after cultures were collected only when clinically indicated; sur-3 days there was no microbiological evidence that vancoveillance blood cultures for asymptomatic, afebrile patients mycin was necessary, vancomycin was discontinued, and were not done. Samples were cultured using the BACTEC pen/cef prophylaxis was resumed in the 'pen/cef' group. In 9240 system (Becton Dickinson Diagnostic Instruments all groups, if an organism was isolated, therapy was Systems, Sparks, MD, USA).
adjusted as indicated based on susceptibility results.
Definition of GPB Statistical analysis
Subjects were grouped for analysis into three cohorts, Early GPB was defined as one or more positive blood cultures for any gram-positive organism 28 from day Ϫ1 until according to the time periods when the three different prophylaxis protocols were in use, ie 1/8/93-29/1/94 was the single most common type of BMT (41%), the remainder being approximately evenly divided between ('vanco'), 14/2/94-9/6/94 ('none'), and 17/6/94-30/12/94 ('pen/cef'). An 'intent to treat' analysis was performed.
related and unrelated allogeneic donor BMT. Most subjects (84%) had a malignancy as the indication for BMT. The Two different measures of GPB occurrence were calculated to describe the experience with GPB in the study median time to neutrophil engraftment was nearly 3 weeks. population. The first measure was the incidence density, which was used to describe the total rate of GPB between
Incidence and correlates of GPB day Ϫ1 and day ϩ30 following BMT. It was defined as the total number of GPB episodes per 1000 patient days.
Of the 289 subjects, 68 (24%) developed GPB in the first Statistical comparisons of the incidence density were com-30 days post-BMT. The Kaplan-Meier estimated timepleted by using the Mantel-Haenzel 2 test for person-years dependent incidence of GPB was also 24% (Table 2 ). data. The second measure of GPB occurrence was the timeSeven patients developed two different episodes of GPB, dependent incidence of GPB. The incidence was estimated which in only one instance were both due to the same by the Kaplan-Meier method, treating first GPB episodes organism. This resulted in a total of 75 GPB episodes, for as the events and censoring patients at time of death. Unian incidence density of nine episodes/1000 patients days variate comparisons were completed by using the log-rank (Table 2) . statistic, and multiple regression analysis was performed All GPB episodes except for four involved a single gramusing the Cox proportional hazards model. Analysis of surpositive organism. The four polymicrobial episodes, which vival was evaluated with the same methods used to evaluate involved two gram-positive organisms each, included one incidence of GPB.
with both S. sanguis and S. salivarius and three with coaguIn order to test the equality of the distribution of patient lase-negative staphylococcus plus corynebacterium, lactocharacteristics across prophylaxis cohorts, Pearson's 2 test bacillus, or a second strain of coagulase-negative staphylowas employed. Statistical comparisons of the length of vancoccus (Table 3 ) (an additional subject had Xanthomonas comycin use and of the day of initiation of vancomycin use maltophilia isolated from the same blood culture that grew among the three different prophylaxis cohorts were carried a coagulase-negative staphylococcus). Coagulase-negative out by using the Wilcoxon rank-sum test.
staphylococcus accounted for 65% and viridans streptococcus for 22% of all GPB isolates, with miscellaneous gram-positive organisms accounting for the remainder Results (Table 3) . No Staphylococcus aureus bacteremia was documented during the study period. Characteristics of study population (Table 1) Of the 75 episodes of GPB, 48 (64%) involved only a single positive blood culture, whereas 27 (36%) had mulSubjects in the three prophylaxis groups were similar with respect to distribution of gender, age, type of BMT, undertiple blood cultures positive for the same organisms. The proportion of GPB episodes with a single positive blood lying disease, time to engraftment, and occurrence of acute graft-versus-host-disease. In the total study population, culture was similar in the vancomycin, 'none', and pen/cef cohorts (3/12 (25%), 11/30 (37%), and 13/33 (39%), males and females were approximately equally represented. The overall median age was 30 years. Autologous BMT respectively; P Ͼ 0.40 for all comparisons). Multiple posi- Vanco = vancomycin; Pen/cef = penicillin/cefazolin; AGVHD = acute graft-versus-host disease. a P values represent comparisons between all three prophylaxis groups. Table 2 Incidence of GPB according to antimicrobial prophylaxis cohort tive cultures were significantly more likely in GPB episodes did not (15%; P = 0.02), and was similar for coagulasethat involved coagulase-negative staphylococcus (24/50, negative staphylococcal bacteremia (29%; n = 48) and viri-48%) as compared with all other organisms combined dans streptococcal bacteremia (27%; n = 15). By multiple (3/25, 12%; P = 0.002), or specifically viridans streptoregression analysis, mortality was also greater among subcoccus (3/16, 19%; P = 0.046). Three GPB episodes led to jects age у18 years as opposed to Ͻ18 years (RR 3.0; removal of the patient's right atrial catheter; each involved 95% CI 1.4-6.3; P = 0.04), those with related (RR 3.1, a single positive blood culture (one each with coagulase-95% CI 1.1-9.3) or unrelated (RR 5.0, 95% CI 1.7-14.9; negative staphylococcus, Bacillus spp., and S. mitis). P Ͻ 0.01) donors as opposed to autologous recipients, and Although both of the patients with coagulase-negative was lower for chronic leukemia (RR 0.4, 95% CI 0.1-1.0; staphylococcal bacteremia for whom severe clinical mani-P = 0.05) than for aplastic anemia or metabolic disorders. festations ('shock' and 'sepsis', respectively) were recorded
In a multiple regression model that incorporated age, transin the BMT complications log had multiple positive blood plant type and underlying diagnosis, GPB remained sigcultures at the time of their GPB episode, the index subject nificantly associated with mortality (RR 2.2, 95% CI 1.2-(who had fatal viridans streptococcal sepsis) had only a 4.1; P = 0.02). single blood culture positive for S. mitis. Despite GPB's association with mortality, GPB was By univariate analysis, the incidence of GPB was not judged by the attending physician to have contributed to significantly associated with gender, type of underlying disdeath in only five subjects, only one of whom had GPB as ease, age, transplant type, or acute graft-versus-host disease the sole recognized cause of death. This subject died with (not shown). Multiple regression analysis yielded similar multi-system organ failure 6 days after detection of viridans results, except that after adjusting for other clinical varistreptococcal bacteremia. The other four subjects with ables GPB was found to be significantly more common GPB-associated death each had other contributory factors among subjects у18 years old than among those Ͻ18 as well, and died 12, 12, 26 or 55 days after detection of (relative risk (RR) = 2.2; 95% CI 1.1-4.2; P = 0.02).
coagulase-negative staphylococcal bacteremia (three Mortality at day 100 was significantly higher among subjects) or viridans streptococcal bacteremia (one subject). patients who developed GPB (27%) than among those who (Table 4) . Of the five subjects in whom GPB was judged to have contributed to death, one was in the 'none' cohort Prophylaxis with vancomycin (and, to a lesser extent, and four were in the 'pen/cef' cohort (P Ͼ 0.10 for compen/cef) was associated with a significantly reduced inciparisons between the three cohorts). All patients with viriddence and later onset of GPB. The incidence and incidence ans streptococcal bacteremia (other than the index subject density of GPB were only a quarter as great in the 'vanco' in the 'none' cohort, who developed fatal septic shock) group, and two-thirds as great in the 'pen/cef' group, as in recovered from the viridans streptococcal bacteremia epithe 'none' group (Table 2) . Among subjects who developed sode with appropriate antimicrobial therapy. GPB, the median time to first documented GPB was three times as long in the 'vanco' group, and twice as long in Impact of prophylaxis protocols on other infections and the 'pen/cef' group, as in the 'no Px' group (Table 2, Figure  vancomycin use  1) . By multiple regression analysis, none of the other clinical factors evaluated (Table 1 ) had a significant conThere was no significant difference between the three founding effect on the association of prophylaxis protocol prophylaxis groups with respect to the incidence of fungewith the incidence of GPB (not shown).
Impact of prophylaxis protocols on GPB
mia, gram-negative bacteremia, or total infection-associated The impact of antimicrobial prophylaxis on GPB was mortality. Fungemia was documented in only three patients both protocol and organism specific (Table 3) . Compared in the 'vanco' group and two patients each in the 'none' and with no prophylaxis, vancomycin prophylaxis appeared to 'pen/cef' groups. Gram-negative bacteremia was similarly substantially reduce the frequency of bacteremia due to infrequent in each of the three prophylaxis groups (5%, coagulase-negative staphylococcus and to completely elim-'vanco'; 9%, 'none'; 7%, 'pen/cef'; P = 0.55). Infections inate viridans streptococcal bacteremia. Pen/cef prophylaxis were judged as having contributed to death in 10 (9%) subhad a more modest protective effect.
jects in the 'vanco' group, four (6%) in the 'none' group, and 15 (13%) in the 'pen/cef' group. Of these infections, 13 were fungal (four 'vanco'; two 'none'; seven 'pen/cef'), Impact of prophylaxis protocol on mortality two were viral (both 'none'), four involved gram-negative Despite the substantial effect of antibiotic prophylaxis bacteria (all 'vanco'), and five were of unspecified type against GPB in general, and against viridans streptococcal (two each, 'vanco' and 'pen/cef'; one, 'none'). bacteremia in particular (Table 2, Figure 1) , there was no apparent improvement in survival associated with GPB Use of vancomycin in different prophylaxis groups prophylaxis. In the whole population, at day +100 after BMT there was no suggestion of a survival difference
In the 'vanco' group, vancomycin therapy was routinely between the three prophylaxis cohorts (P Ͼ 0.30) (Table started on day Ϫ1 for afebrile patients as prophylaxis, and 4). Multiple regression analysis confirmed that the three in some patients was started even prior to BMT as empiric prophylaxis cohorts did not differ significantly with respect therapy for fever. However, vancomycin also was used in to day +100 mortality, even when other clinical factors the 'none' and 'pen/cef' groups as part of the empiric therwere included in the model (not shown).
apy for the first febrile episode, which occurred at a median Among the subset of subjects who did develop GPB of day +4 or +5 post-BMT (Table 5 ); these subjects also there was no significant difference in +7 day or +30 day received empiric vancomycin therapy for at least 72 h dursurvival after GPB between the three prophylaxis cohorts ing any subsequent febrile episodes. Thus, despite not receiving vancomycin prophylactically, 93% of 'none' subjects and 82% of 'pen/cef' subjects did receive vancomycin at some point during the study period. None the less, the 'none' and 'pen/cef' subjects received substantially fewer total days of vancomycin therapy (median of 6 and 7 days, respectively; the equivalent of two 72-h periods of empiric therapy) than did the 'vanco' patients (median 24 days) (P Ͻ 0.001).
Antimicrobial susceptibility patterns of GPB isolates
Susceptibility results were available for 76 (96%) of the 79 GPB isolates. With the exception of the single lactobacillus isolates, all isolates were susceptible to vancomycin. All but three coagulase-negative staphylococcus isolates were resistant to methicillin and penicillin, whereas three (one coccal isolates for which susceptibility results were avail- Table 4 Survival post-BMT or post-GPB according to antimicrobial prophylaxis cohort 
Group
Initiation of vancomycin, median day Ϫ1 (Ϫ8, Ϫ1) b Pharmacy records were reviewed for 50 subjects in the 'vanco' group, all of whom received vanco, and for all subjects in the 'none' and 'pen/cef' groups, of whom 67/68 (99%) and 99/115 (86%), respectively, received vanco as empirical therapy during febrile episodes. c For subjects in the 'vanco' group who received vancomycin prior to day Ϫ1, and for all subjects in the 'none' and 'pen/cef' groups, vancomycin was given not for prophylaxis but for empiric therapy (for 72 h, during febrile episodes) or as defined therapy (for documented gram-positive infections requiring vancomycin). able were fully susceptible to penicillin; another seven We found that GPB was significantly associated with mortality. However, our data suggest that among BMT (44%) exhibited intermediate susceptibility, and two (13%) were fully resistant. A greater proportion of these isolates recipients GPB is rarely a contributing cause of death, 5 since in only five subjects (of 52 who died by day +100) were sensitive to cefazolin (15/16, 94%) than were sensitive to penicillin (7/16, 44%; P = 0.003). Penicillin susceptiwas GPB considered to have contributed to death, only two deaths occurred within 7 days of a GPB episode, and only bility among viridans streptococci was somewhat more common in the 'none' cohort (6/10) than in the 'pen/cef' one of these deaths (in a patient with viridans streptococcal bacteremia and septic shock) was directly attributable to cohort (1/6; P = 0.15), and the sole cefazolin-resistant isolate occurred in the 'pen/cef' cohort. the antecedent GPB. Thus, GPB may be primarily a marker for, rather than a cause of, increased mortality following BMT. In our evaluation of 289 consecutive BMT recipients, the index case of fatal viridans streptococcal sepsis Discussion was the only clear example of a death that could have been prevented by vancomycin prophylaxis. As such, this case In this retrospective analysis of prospectively collected data from 289 consecutive BMT recipients, prophylaxis against remains an anecdote, of uncertain broader significance. Our findings suggest that in almost all cases GPB in GPB with vancomycin or pen/cef did not confer a significant reduction in mortality either in the total population or BMT recipients can be managed successfully with appropriate antimicrobial therapy, including empiric therapy of among subjects who developed GPB. Although our study lacked the power to exclude a small survival benefit from fever with agents active against gram-positive organisms, even if such therapy is initiated after the onset of overt GPB prophylaxis (Table 4) , the absence of even a consistent trend towards improved survival in the active prophyclinical manifestations of GPB. Although the incidence of GPB can be reduced substantially by effective antimicrolaxis cohorts argues against the hypothesis that mortality can be reduced by preventing GPB.
bial prophylaxis, this has little or no apparent impact on mortality. These considerations argue that vancomycin is whom have indwelling right atrial catheters which predispose to bacteremia with skin organisms, and many of whom not needed as routine prophylaxis after BMT.
We also found that prophylaxis protocols without vancoare receiving prophylactic or therapeutic antimicrobial agents that could render blood cultures falsely negative mycin (ie either no prophylaxis or pen/cef) reduced vancomycin usage by 75%. Our data suggest that avoidance of even in the presence of true bacteremia, a single positive blood culture (even with skin flora) should be even more vancomycin prophylaxis, which is consistent with current guidelines regarding vancomycin use from the Hospital predictive of true bacteremia than is the case in the general hospital population. Moreover, the stakes are higher with Infection Control Practices Advisory Committee (HICPAC) to reduce the emergence of vancomycin-resistant entero-BMT recipients. Bacteremia is likely to be poorly tolerated, so single positive cultures could be disregarded as reflecting cocci, 27 can be done safely in BMT recipients. It should be noted that our data do not specifically address the related contamination only at substantial risk to the patient. Of note, coagulase-negative staphylococcus, a skin sapquestion of whether vancomycin should be included as part of the empiric antimicrobial regimen for febrile episodes in rophyte which in other contexts is one of the organisms most commonly isolated from a single blood culture bottle neutropenic BMT recipients. [29] [30] [31] This practice is standard on the UMHC BMT service, but is advised against in the and thus regarded as a contaminant, 32 in the present study was proportionally more likely than any other organism to HICPAC guidelines on vancomycin use for patients who lack overt clinical evidence of a catheter-associated infecbe found in multiple cultures. The only other organism that caused episodes of multiple-positive-culture GPB was virition. 27 It may be that the successful management of most GPB episodes observed in the 'pen/cef' and 'none' cohorts dans streptococcus. Paradoxically, and in significant contrast to coagulase-negative staphylococcus, this more viruresulted from this routine empiric therapeutic use of vancomycin, although alternative approaches might have yielded lent pathogen was isolated from only a single blood culture in 81% of the GPB episodes it caused, including that of equally good outcomes. 30, 31 Antibiotic prophylaxis against GPB appeared to have the the fatal index case. Thus, internal evidence from the present study suggests that in early post-BMT febrile predictable effect of selectively eliminating the most antibiotic-susceptible organisms, thereby enriching the patients the number of blood cultures positive should not be relied upon to discriminate between true bacteremia resulting bacterial pool with more antibiotic-resistant organisms. Almost all of the GPB isolates in the vancomyand contamination. Although the present study involved sequential (rather cin cohort were (multi-resistant) methicillin-resistant coagulase-negative staphylococci, against which vancomycin than concurrent) treatment groups and was not randomized, several aspects of the study argue for the validity of the was usually the only active agent. Penicillin prophylaxis and prior exposure to other beta lactam agents have been findings and against the existence of significant confounding variables. These included the uniformity of the associated in other studies with the development of penicillin-resistant viridans streptococcal bacteremia among BMT three cohorts with respect to the measured clinical characteristics, the absence in regression analysis of identifiable recipients, 6, 20, 21, 23 and in the present study, viridans streptococci exhibited a trend toward reduced penicillin suscepticonfounding variables on the associations between prophylaxis protocol and GPB or mortality, the systematic and bility in the pen/cef cohort as compared with the 'none' cohort. Of note, however, was their largely preserved susconsecutive allocation to sequential prophylaxis protocols, and the standardized prospective approach to data ceptibility to cefazolin. Ironically, the index subject's lethal viridans streptococcal isolate was susceptible to all agents collection. The present study constitutes the largest clinical evaluation of vancomycin prophylaxis among BMT tested.
We were unable to analyze in detail the impact of the recipients. 6, 10, 11, 15 In summary, we found that although prophylaxis with three prophylaxis protocols on other potentially relevant clinical endpoints, including the number or duration of either vancomycin or pen/cef reduced GPB, such prophylaxis conferred no detectable survival benefit. Avoidance febrile episodes, 7, 15 the number of cultures or radiological evaluations for febrile episodes, the use of other antimicroof vancomycin prophylaxis dramatically reduced the use of vancomycin among BMT recipients, without a significant bial agents (including antifungal agents), 15 rates of removal of implanted central venous catheters in response to docuincrease in total mortality or in deaths due to GPB. mented GPB or culture-negative fevers, and total costs. If more febrile episodes occurred among patients receiving no
